According to filings with the U.S. Securities and Exchange Commission, DiaMedica Therapeutics is raising up to $30,100,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About DiaMedica Therapeutics
DiaMedica Therapeutics is committed to improving the lives of individuals battling serious vascular diseases by developing innovative therapies that reduce ischemia. With an initial focus on preeclampsia (PE) and acute ischemic stroke (AIS), we are dedicated to advancing patient care through a novel approach that centers around improving blood flow to ischemic tissue (collateral circulation) to improve patient outcomes.

To learn more about DiaMedica Therapeutics, visit https://www.diamedica.com/
DiaMedica Therapeutics Linkedin Page: https://www.linkedin.com/company/diamedica/

Contact:
Scott Kellen, Chief Financial Officer
763-496-5454
https://www.linkedin.com/in/scottkellen/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.